Trial · NCT07912177
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | OCD symptom severity is measured by the self-report Yale-Brown Obsessive-Compulsive Scale, Second Edition (Y-BOCS-II; Storch et al., 2010). The Y-BOCS-II has 10 items pertaining to obsessions and compulsions rated on a Likert scale. Scores range from 0 to 40 with higher scores indicating increased symptom severity. |
| Primary | Change in Quality of Life from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | Quality of life is measured by the Illness Intrusiveness Rating Scale (IIRS; Devins, 1994). The IIRS is a 13-item self-report measure of the degree to which symptoms interfere with important life domains (e.g., work, family relationships). Total scores range from 13 (minimum intrusiveness) to 91 (extreme intrusiveness). |
| Primary | Change in Functional Impairment from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | Functional Impairment is measured by: 1. The Sheehan Disability Scale (SDS; Sheehan et al., 1983). The SDS is a brief measure of disability and functional impairment due to psychiatric or medical symptoms focused on work, social life/leisure activities, and family life/home responsibilities. Scores range from 0 (unimpaired) to 30 (highly impaired). 2. The Family Functioning Scale (FFS; Stewart et al., 2017). The FFS is a self-report scale of how much family impairment arises from OCD symptoms. Scores range from 0 to 63 with higher scores indicating increased family impairment. |
| Secondary | Change in Family Accommodation from Baseline to 3-Months Post-Treatment (Family Member Self- Report) | Baseline to 3-Months Post-Treatment | Family Accommodation is measured by the Family Accommodation Scale for Obsessive-Compulsive Disorder - Self-Rated Version (FAS-SR, Pinto et al., 2013). The FAS-SR is a 19-item self-report measure that gathers information about the degree to which family members participate in accommodating behaviours. Scores range from 0 to 76 with higher scores indicating more family accommodation. |
| Secondary | Change in Family Accommodation from Baseline to 3-Months Post-Treatment (Patient Self- Report) | Baseline to 3-Months Post-Treatment | Family Accommodation is measured by the Family Accommodation Scale for Obsessive-Compulsive Disorder - Patient Version (FAS-PV; Wu et al., 2016) is a 19-item self-report measure that gathers information about the degree to which an OCD patient's family member participates in accommodating behaviours. Scores range from 0 to 76 with higher scores indicating more family accommodation. |
| Secondary | Change in OCD Symptom Severity from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | OCD symptom severity is measured by the self-report Yale-Brown Obsessive-Compulsive Scale, Second Edition (Y-BOCS-II; Storch et al., 2010). This will be administered to family members as well given the tendency for OCD symptoms to cluster within families. The Y-BOCS-II has 10 items pertaining to obsessions and compulsions rated on a Likert scale. Scores range from 0 to 40 with higher scores indicating increased symptom severity. |
| Secondary | Change in Severity of Depression, Anxiety, and Stress from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | The Depression Anxiety Stress Scale-21 (DASS-21; Lovibond \& Lovibond, 1995) is a 21-item self-report measure designed to assess the severity of depression, anxiety, and stress symptoms. Scores range from 0 to 63 on each of the subscales (Depression, Anxiety, and Stress), with higher scores indicating increased symptom severity. |
| Secondary | Change in Severity of Depression, Anxiety, and Stress from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | The Depression Anxiety Stress Scale-21 (DASS-21; Lovibond \& Lovibond, 1995) is a 21-item self-report measure designed to assess the severity of depression, anxiety, and stress symptoms. Scores range from 0 to 63 on each of the subscales (Depression, Anxiety, and Stress), with higher scores indicating increased symptom severity. |
| Secondary | Change in Quality of Life from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | Quality of life is measured by the Illness Intrusiveness Rating Scale (IIRS; Devins, 1994). The IIRS is a 13-item self-report measure of the degree to which symptoms interfere with important life domains (e.g., work, family relationships). Total scores range from 13 (minimum intrusiveness) to 91 (extreme intrusiveness). |
| Secondary | Change in Functional Impairment from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | Functional Impairment is measured by the Sheehan Disability Scale (SDS; Sheehan et al., 1983). The SDS is a brief measure of disability and functional impairment due to psychiatric or medical symptoms focused on work, social life/leisure activities, and family life/home responsibilities. Scores range from 0 (unimpaired) to 30 (highly impaired). |
| Secondary | Change in Family Functional Impairment from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | Family Functional Impairment is measured by the Family Functioning Scale (FFS; Stewart et al., 2017). The FFS is a self-report scale of how much family impairment arises from OCD. Scores range from 0 to 63 with higher scores indicating increased family impairment. |
| Secondary | Change in Emotional Expression from Baseline to 3-Months Post-Treatment (Family Member Self-Report) | Baseline to 3-Months Post-Treatment | Emotional expression is measured by the Family Questionnaire (FQ; Wiedemann, Rayki, Feinstein, \& Hahlweg, 2002). The FQ is a 20 items self-report measure of criticism and emotional overinvolvement. Scores range from 20 to 80, with higher scores indicating greater levels of expressed emotion. |
| Secondary | Change in Perception of Expressed Emotion from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | Perception of Expressed Emotion is measured by the Brief Dyadic Scale of Expressed Emotion (BDSEE; Medina-Pradas et al., 2011). The BDSEE is a 14 item scale assessing patients' perceptions of loved ones' expressed emotions on two components: Critical comments and Emotional overinvolvement. Scores range from 0 to 140 with higher scores indicating higher levels of criticism, hostility, and emotional overinvolvement within close relationships. |
| Secondary | Change in Obsessive-Compulsive Characteristics from Baseline to 3-Months Post-Treatment (Patient Self-Report) | Baseline to 3-Months Post-Treatment | Obsessive-Compulsive Characteristics are measured by the Obsessive-Compulsive Trait Core Dimensions Questionnaire (OC-TCDQ; Summerfeldt et al., 2014). the OC-TCDQ is a 20- item self-report measure scored across two dimensions: Harm Avoidance (HA) and Incompleteness (INC). Scores range from 20 to 100 with higher scores indicating stronger motivational tendencies toward harm avoidance and/or incompleteness. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07912177/registered